Skip to main content
Clinical Trials/NCT01246336
NCT01246336
Completed
Not Applicable

Exploratory Study to Detect Volatile Biomarkers of Idiopathic Parkinson's Disease and Parkinsonism From Exhaled Breath Using a Nanomedical Artificial Olfactory System.

Rambam Health Care Campus0 sites41 target enrollmentAugust 2009

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Parkinson's Disease
Sponsor
Rambam Health Care Campus
Enrollment
41
Primary Endpoint
Nanosensory detection
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

Parkinson's disease is diagnosed clinically, because biomarkers that may help in diagnosis and differential diagnosis are not yet available. Exhaled breath testing may yield a "breath-print" that can be used to distinguish healthy and diseased states.

Registry
clinicaltrials.gov
Start Date
August 2009
End Date
January 2012
Last Updated
8 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Ilana Schlesinger

Ilana Schleainger, Rambam Health Care Campus

Rambam Health Care Campus

Eligibility Criteria

Inclusion Criteria

  • Patients with Parkinsonism

Exclusion Criteria

  • Severe dementia

Outcomes

Primary Outcomes

Nanosensory detection

Time Frame: immediate

analyze combinations of nanomaterial-based sensors (organically functionalized carbon nanotubes and gold nanoparticles)

Similar Trials